Dabigatran and kidney disease: a bad combination. - Wikidata - awgldk - TriplyDB

Dabigatran and kidney disease: a bad combination.

Dabigatran and kidney disease: a bad combination.

http://www.wikidata.org/entity/Q38122675

about

Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.Dabigatran-Related Nephropathy in a Patient with Undiagnosed IgA Nephropathy Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity.Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.Nephrology

P2860

Q35187005-002B8125-CC8F-4708-A542-0117B0646F85 Q35683869-A3D59EC4-9582-45EA-A42A-7B5C57F8FFF4 Q35968902-D375B8AB-3D72-4A64-922A-8E95B27B58C1 Q38624595-C9A94466-194A-4381-B11B-9BDE8EBB6B86 Q39120056-512C861A-CA09-49A0-B40D-76A2AED7D7A3 Q48375140-882B5BC1-036B-4A41-9DDA-F447105CA55A Q59192050-AF2D19C0-E992-419B-9100-312FA155ECDB

P2860

Dabigatran and kidney disease: a bad combination.

http://www.wikidata.org/entity/Q38122675

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Dabigatran and kidney disease: a bad combination.

@en

type

label

Dabigatran and kidney disease: a bad combination.

@en

prefLabel

Dabigatran and kidney disease: a bad combination.

@en

P1433

Q38122675-482E3402-E0AE-4B01-AF76-F479BF5A8B0C

P1476

Q38122675-067BBFB9-4B53-4443-8946-E9B3694DC435

P2093

Q38122675-11B2E2C1-C1B7-43E4-BC24-DC051DC74D17

Q38122675-4A18FD19-29CC-4821-A527-568DE5221DDA

Q38122675-D9776057-7A5A-464F-85AA-252457AF8008

Q38122675-E53C809D-6B8F-489B-92EF-35DF44217398

P2860

Q38122675-004311DD-6A32-486F-8BBD-2B02CAA1F581

Q38122675-1FC28118-5C6E-4C07-B1EF-9EE0B982F4AC

Q38122675-2725C828-8384-4E86-BCF1-440F56E1E0AB

Q38122675-2D98AD10-2C0A-4003-93DF-392DC9129E71

Q38122675-3604536E-4939-4226-A226-061EB9D087CF

Q38122675-3D5F047A-3160-4E95-AAF4-3FC1A7CBE078

Q38122675-3F5242A5-8F50-4B27-A81F-3CE1AB279FA3

Q38122675-45E8B54E-64F7-4477-8F30-C710FB228705

Q38122675-49F42773-22DF-49C0-9DAA-C9DC9D60FA0F

Q38122675-4B0D80C0-4375-4F71-B16A-F457FFC8BD76

P304

Q38122675-56FF367C-2431-4D32-AC7C-9F5544CDDF9D

P31

Q38122675-6382BA9C-DAD2-4CA8-8212-321866942061

P356

Q38122675-273DCAA8-7E75-4617-9771-002BB40B8AC5

P433

Q38122675-AC1D5F2B-C7B3-4A20-B145-A6C769A3E410

P478

Q38122675-9ED0097A-A1E0-404F-98E5-180A26C39856

P577

Q38122675-12ECC6AA-5A71-4D2A-A046-F3A0FAF7C4FD

P5875

Q38122675-194D9A73-908D-40B1-9C8D-636C47D0AB5F

P698

Q38122675-5699CECC-62B8-4AC1-822A-A0D0954EDAF0

P932

Q38122675-8B60EA92-540C-4E05-B508-17F63988DBE6

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Dabigatran and kidney disease: a bad combination.

@en

P2093

C Michael Chaknos

http://www.w3.org/2001/XMLSchema#string

Felix Knauf

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Berns

http://www.w3.org/2001/XMLSchema#string

Mark A Perazella

http://www.w3.org/2001/XMLSchema#string

P2860

Structure-based design of novel potent nonpeptide thrombin inhibitors

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Dabigatran versus warfarin in patients with atrial fibrillation

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

Hemorrhagic complications associated with dabigatran use.

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

Warfarin versus new agents: interpreting the data.

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

P304

1591-1597

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.01260213

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

250920505

http://www.w3.org/2001/XMLSchema#string

P698

23868901

http://www.w3.org/2001/XMLSchema#string

P932

3805067

http://www.w3.org/2001/XMLSchema#string